{"schema_version":"1.0","type":"article","title":"Kelun's TROP2 ADC wins on survival in late-line gastric cancer: the China-made asset Merck keeps cashing","url":"https://drugnews.com.tw/articles/2026-11-21-merck-kelun-trop2-adc-gastric-phase3-os-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-21-merck-kelun-trop2-adc-gastric-phase3-os-en.md","lang":"en","date":"2026-11-21","publish_at":"2026-11-21T20:00:00+08:00","updated_at":"2026-11-21","category":"醫學大會","topic":"BD / 授權","tags":["ADC","TROP2","gastric cancer","oncology","licensing"],"summary":"Merck's TroFuse-015 met its overall-survival endpoint in previously treated gastroesophageal adenocarcinoma. The progression-free survival endpoint was not met.","key_points":["TroFuse-015 met its primary overall-survival endpoint.","Progression-free survival by blinded central review was not met.","Kelun-Biotech retained development and commercial rights in its home territory, including Taiwan."],"facts":[],"sections":["What Merck reported, and what it held back","The deal behind the drug","Same yardstick: Daiichi Sankyo's Enhertu in third-line gastric","Why this matters for Asian assets","What evidence is still missing","Our call","What to watch","Sources"],"references":[],"images":[{"alt":"Figure 1 | How sac-TMT enters a tumor cell","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os-en/figure-01.png"},{"alt":"Figure 2 | TroFuse-015 design and results","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os-en/figure-02.png"},{"alt":"Figure 3 | Upfront payments, milestones and licensing territories","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os-en/figure-03.png"},{"alt":"Median overall survival · 12.5 · Enhertu · 8.4 months · physician's choice","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os-en/inline-card-comparison-15cba840a551.png"},{"alt":"2.1-month · median survival gain over placebo","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os-en/inline-card-number-7026b5e4c685.png"},{"alt":"Figure 4 | Selected TROP2 ADC Phase 3 readouts","url":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/merck-kelun-trop2-adc-gastric-phase3-os-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-21）。Kelun's TROP2 ADC wins on survival in late-line gastric cancer: the China-made asset Merck keeps cashing。https://drugnews.com.tw/articles/2026-11-21-merck-kelun-trop2-adc-gastric-phase3-os-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"What are the key developments in “TroFuse-015 met its primary overall-survival endpoint”?","a":"TroFuse-015 met its primary overall-survival endpoint."},{"q":"What are the key developments in “Progression-free survival by blinded central review was not met”?","a":"Progression-free survival by blinded central review was not met."},{"q":"What are the key developments in “Kelun-Biotech retained development and commercial rights in its home territory, including Taiwan”?","a":"Kelun-Biotech retained development and commercial rights in its home territory, including Taiwan."}]}